FUSN Live-Signale | Maximieren Sie Profite mit Getagraph.com

VERKAUFEN 107853 min ago

@ $11.17

Ausgestellt: 14 Feb 2024 @ 21:35

Rendite: 91.58%

Vorheriges Signal: Feb 14 - 20:36

Vorheriges Signal: Kaufen

Rendite: 1.92 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 20:08):

Stats
Tagesvolumen	263 151
Durchschnittsvolumen	2.15M
Marktkapitalisierung	1.82B
EPS	$-0.390 ( 2024-03-21 )
Nächstes Ertragsdatum	( $-0.370 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-14.76
ATR14	$0.00500 (0.02%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-04	Leamon Christopher P	Buy	106 100	Stock Option (Right to Buy)
2024-01-04	Leamon Christopher P	Buy	63 700	Restricted Stock Units
2023-08-31	Leamon Christopher P	Buy	11 957	Common Stock
2024-01-04	Crowley John J	Buy	106 100	Stock Option (Right to Buy)
2024-01-04	Crowley John J	Buy	63 700	Restricted Stock Units

INSIDER POWER
99.99
Last 91 transactions
Buy: 6 470 725 \| Sell: 164 236

Volumen Korrelation

Lang: -0.01 (neutral)

Kurz: -0.43 (neutral)

Signal:(56.153) Neutral

Fusion Pharmaceuticals Korrelation

10 Am meisten positiv korreliert
ISEM	0.881
ADRE	0.876
IDLB	0.83
ISDX	0.827
OVLY	0.808
IQ	0.806
BSCE	0.803

10 Am meisten negativ korreliert
AUID	-0.84
RMCF	-0.831
CMLFU	-0.822
RMRM	-0.816
IRBT	-0.807
CNXN	-0.802
TIVC	-0.801

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Fusion Pharmaceuticals Korrelation - Währung/Rohstoff

0.41
( neutral )

0.43
( neutral )

0.00
( neutral )

-0.83
( strong negative )

0.59
( weak )

Fusion Pharmaceuticals Finanzdaten

Annual	2023
Umsatz:	$2.07M
Bruttogewinn:	$723 000 (34.96 %)
EPS:	$-1.450

FY	2023
Umsatz:	$2.07M
Bruttogewinn:	$723 000 (34.96 %)
EPS:	$-1.450

FY	2022
Umsatz:	$1.46M
Bruttogewinn:	$-57.43M (-3 931.14 %)
EPS:	$-2.00

FY	2021
Umsatz:	$1.44M
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$-1.884

Financial Reports:

No articles found.

Fusion Pharmaceuticals

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company has a strategic collaboration agreement with AstraZeneca UK Limited to jointly discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.